×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
07:39 pm
lly
Why Eli Lilly Stock Flopped on Friday [Globe and Mail, The (Toronto, Canada)]
Low
Report
Why Eli Lilly Stock Flopped on Friday [Globe and Mail, The (Toronto, Canada)]
4/24
07:02 pm
lly
Why Eli Lilly Stock Flopped on Friday [Yahoo! Finance]
Low
Report
Why Eli Lilly Stock Flopped on Friday [Yahoo! Finance]
4/24
04:22 pm
lly
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 [Seeking Alpha]
Low
Report
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 [Seeking Alpha]
4/24
02:03 pm
lly
Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race [Yahoo! Finance]
Low
Report
Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race [Yahoo! Finance]
4/24
11:17 am
lly
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims [Yahoo! Finance]
Low
Report
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims [Yahoo! Finance]
4/24
10:24 am
lly
Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions [Yahoo! Finance]
Low
Report
Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions [Yahoo! Finance]
4/23
09:29 pm
lly
Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock? [Yahoo! Finance]
Medium
Report
Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock? [Yahoo! Finance]
4/23
06:15 am
lly
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Low
Report
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/21
04:21 pm
lly
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Sulzberger Gabrielle
4/21
04:19 pm
lly
Form 4 ELI LILLY & Co For: Apr 20 Filed by: LUCIANO JUAN R
Low
Report
Form 4 ELI LILLY & Co For: Apr 20 Filed by: LUCIANO JUAN R
4/21
04:17 pm
lly
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Fyrwald J Erik
Low
Report
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Fyrwald J Erik
4/21
04:14 pm
lly
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Alvarez Ralph
Low
Report
Form 4 ELI LILLY & Co For: Apr 20 Filed by: Alvarez Ralph
4/20
03:25 pm
lly
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
Low
Report
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
3/26
06:03 pm
lly
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ELI LILLY & Co Filed by: VANGUARD GROUP INC
3/20
04:20 pm
lly
Form DEF 14A ELI LILLY & Co For: Mar 20
Low
Report
Form DEF 14A ELI LILLY & Co For: Mar 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: